AIM ImmunoTech Inc. (AIM)

🚫 AIM ImmunoTech Inc. does not pay dividends

Company News

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire Inc. • Thomas K. Equels • August 15, 2025

AIM ImmunoTech reported positive mid-year data for Ampligen in pancreatic cancer treatment, combining with AstraZeneca's Imfinzi, and raised $8 million in a public equity offering to fund operations for approximately 12 months.

AZN
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
Benzinga • Avi Kapoor • March 25, 2024

The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Citizens The Trade: Citizens, Inc. (NYSE: CIA) President and CEO Gerald Shields acquired a total of 17,466 shares an average price of $2.26. To acquire these shares, it cost around $39,475. What’s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens. What Citizens Does: Citizens Inc is ...

CIA
5 Penny Stocks To Watch After Big News This Week
PennyStocks • J. Samuel • January 17, 2023

Penny stocks to watch with news that are turning heads in the stock market this week. The post 5 Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.